Latest Oncogene Stories

Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York SAN DIEGO, June 3, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Jefferies 2013 Global Healthcare Conference in New York on Thursday, June 6, 2013 at 3:00 p.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for...

A University of Colorado Cancer Center study recently published in the journal Cell Death & Disease shows that turning up a few microRNAs a little may offer as much anti-breast-cancer activity as turning up one microRNA a lot – and without the unwanted side effects. It’s a bit like the classic thought experiment known as the “tumor problem” formulated by Karl Dunker in 1945 and used frequently in the problem-solving literature: Imagine a person suffers from a malignant tumor in...

Understanding how oncogenes affect the body clock may help create better cancer treatments The Myc oncogene can disrupt the 24-hour internal rhythm in cancer cells. Postdoctoral fellow Brian Altman, PhD, and graduate student Annie Hsieh, MD, both from the in the lab of Chi Van Dang, MD, PhD, director of the Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, present their data in the "Metabolic Pathway Regulation in...

Mutations in a protein called SPOP (speckle-type POZ protein) disarm it, allowing another protein called steroid receptor coactivator-3 (SRC-3) to encourage the proliferation and spread of prostate cancer cells, said researchers led by those at Baylor College of Medicine in a report that appears online in Proceedings of the National Academy of Sciences. Normally SPOP acts as a tumor suppressor gene by marking SRC-3 for destruction, said Dr. Nicholas Mitsiades, assistant professor of...

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA SAN DIEGO, March 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the 25(th) Annual Roth OC Growth Stock Conference at the Ritz-Carlton Laguna Nigel, in Dana Point, CA on Tuesday, March 19, 2013 at 12:00 p.m....

SAN DIEGO, Feb. 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well and the Company expects to achieve analytical and clinical validation of the test in its CLIA laboratory in March 2013. When validation is completed, the test will be available to clinicians and their patients. In addition to the ongoing HPV validation studies, one clinical trial has been completed...

SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the Leerink Swan Global Healthcare Conference at the Waldorf Astoria Hotel, 301 Park Avenue, NY, NY on Wednesday, February 13, 2013 at 9:00 a.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for one-on-one meetings during...

Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce antibodies specific for the pathogen. However, it is known that the vast majority of lymphomas derive from the B cells at the germinal centers. Now, Dr. Dinis Pedro Calado and Dr. Klaus Rajewsky of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch have identified subgroups of...

Two Mount Sinai School of Medicine researchers are among a select group of scientists from around the world who have been recognized by the National Cancer Institute (NCI) for their quest to answer the most pressing questions about cancer. New York, NY (PRWEB) September 20, 2012 Two Mount Sinai School of Medicine researchers are among a select group of scientists from around the world who have been recognized by the National Cancer Institute (NCI) for their quest to answer the most...

SAN DIEGO, Sep. 4, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 14th Annual Rodman & Renshaw Healthcare Conference at the Waldorf Astoria Hotel, 301 Park Avenue, NY, NY on Monday, September 10, 2012 at 4:55 p.m. Mr. Schuh and Chief Financial Officer Stephen Zaniboni will be available for one-on-one meetings...